Adaptive Biotechnologies Past Earnings Performance
Past criteria checks 0/6
Adaptive Biotechnologies's earnings have been declining at an average annual rate of -16.8%, while the Life Sciences industry saw earnings growing at 11.8% annually. Revenues have been growing at an average rate of 16% per year.
Key information
-16.8%
Earnings growth rate
-7.2%
EPS growth rate
| Life Sciences Industry Growth | 21.5% |
| Revenue growth rate | 16.0% |
| Return on equity | -87.4% |
| Net Margin | -110.1% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Adaptive Biotechnologies: Making Some Progress
Nov 26Adaptive Biotechnologies Corporation's (NASDAQ:ADPT) P/S Is Still On The Mark Following 25% Share Price Bounce
Nov 26
Does Adaptive Biotechnologies (NASDAQ:ADPT) Have A Healthy Balance Sheet?
Nov 01Market Participants Recognise Adaptive Biotechnologies Corporation's (NASDAQ:ADPT) Revenues Pushing Shares 27% Higher
Oct 05Adaptive Biotechnologies Corporation's (NASDAQ:ADPT) Share Price Could Signal Some Risk
Jul 12Is Adaptive Biotechnologies (NASDAQ:ADPT) Using Too Much Debt?
May 08It's Down 26% But Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Could Be Riskier Than It Looks
Apr 03Adaptive Biotechnologies: A Post Earnings Assessment
Feb 25Analysts Just Shaved Their Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Forecasts Dramatically
Feb 17Not Many Are Piling Into Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Stock Yet As It Plummets 25%
Feb 01Analysts Are More Bearish On Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Than They Used To Be
Nov 17Is Adaptive Biotechnologies (NASDAQ:ADPT) A Risky Investment?
Oct 13Is Adaptive Biotechnologies (NASDAQ:ADPT) A Risky Investment?
Jul 06Investors Give Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Shares A 26% Hiding
May 05We're Hopeful That Adaptive Biotechnologies (NASDAQ:ADPT) Will Use Its Cash Wisely
Apr 15Adaptive Biotechnologies (NASDAQ:ADPT) Is In A Good Position To Deliver On Growth Plans
Dec 13Adaptive Biotechnologies, Epic team up to integrate clonoSEQ test in electronic record system
Oct 11Adaptive Biotechnologies announces $250M non-dilutive royalty financing
Sep 12We're Not Very Worried About Adaptive Biotechnologies' (NASDAQ:ADPT) Cash Burn Rate
Aug 14Companies Like Adaptive Biotechnologies (NASDAQ:ADPT) Are In A Position To Invest In Growth
Apr 29Adaptive Biotechnologies: Good Buy For Long-Term Investors
Apr 15Are Investors Undervaluing Adaptive Biotechnologies Corporation (NASDAQ:ADPT) By 22%?
Feb 26Revenue & Expenses Breakdown
How Adaptive Biotechnologies makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 177 | -195 | 161 | 0 |
| 30 Jun 24 | 169 | -213 | 163 | -8 |
| 31 Mar 24 | 175 | -215 | 171 | 0 |
| 31 Dec 23 | 170 | -225 | 173 | 0 |
| 30 Sep 23 | 180 | -196 | 176 | 0 |
| 30 Jun 23 | 190 | -191 | 178 | 55 |
| 31 Mar 23 | 184 | -195 | 177 | 0 |
| 31 Dec 22 | 185 | -200 | 184 | 0 |
| 30 Sep 22 | 168 | -221 | 188 | 0 |
| 30 Jun 22 | 160 | -232 | 191 | 0 |
| 31 Mar 22 | 155 | -229 | 185 | 0 |
| 31 Dec 21 | 154 | -207 | 170 | 0 |
| 30 Sep 21 | 147 | -190 | 152 | 0 |
| 30 Jun 21 | 133 | -171 | 133 | 0 |
| 31 Mar 21 | 116 | -155 | 121 | 0 |
| 31 Dec 20 | 98 | -146 | 111 | 0 |
| 30 Sep 20 | 92 | -122 | 100 | 0 |
| 30 Jun 20 | 92 | -99 | 91 | 0 |
| 31 Mar 20 | 93 | -82 | 80 | 0 |
| 31 Dec 19 | 85 | -70 | 69 | 0 |
| 30 Sep 19 | 78 | -62 | 63 | 0 |
| 30 Jun 19 | 69 | -56 | 56 | 0 |
| 31 Mar 19 | 59 | -53 | 50 | 0 |
| 31 Dec 18 | 56 | -46 | 45 | 0 |
| 31 Dec 17 | 38 | -43 | 33 | 0 |
Quality Earnings: ADPT is currently unprofitable.
Growing Profit Margin: ADPT is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ADPT is unprofitable, and losses have increased over the past 5 years at a rate of 16.8% per year.
Accelerating Growth: Unable to compare ADPT's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ADPT is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (-4.7%).
Return on Equity
High ROE: ADPT has a negative Return on Equity (-87.37%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/10 23:13 |
| End of Day Share Price | 2025/01/10 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Adaptive Biotechnologies Corporation is covered by 15 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Derik de Bruin | BofA Global Research |
| Mark Massaro | BTIG |
| Daniel Leonard | Credit Suisse |